Patents by Inventor Keith A. Webster

Keith A. Webster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9394526
    Abstract: Methods and compositions for the treatment of hypoxia associated disorders by directional angiogenesis/arteriogenesis. Conditionally silenced vectors expressing a therapeutic molecule under hypoxic conditions avoid chaotic vascularization and allow for the orderly growth of new vessels into damaged tissue.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: July 19, 2016
    Assignee: University of Miami
    Inventor: Keith A. Webster
  • Publication number: 20150322410
    Abstract: Methods and compositions for the treatment of hypoxia associated disorders by directional angiogenesis/arteriogenesis. Conditionally silenced vectors expressing a therapeutic molecule under hypoxic conditions avoid chaotic vascularization and allow for the orderly growth of new vessels into damaged tissue.
    Type: Application
    Filed: July 15, 2015
    Publication date: November 12, 2015
    Inventor: KEITH A. WEBSTER
  • Publication number: 20150139952
    Abstract: The methods, compositions, cells and kits described herein are based on the discovery that stem cells, when injected into ischemic tissue of mammals, can be protected by preconditioning of the ischemic tissue with hypoxia-regulated human VEGF and human IGF-1. Methods, compositions, cells and kits for treating tissue injured by ischemia or at risk of ischemic injury in a subject are thus described herein.
    Type: Application
    Filed: August 11, 2014
    Publication date: May 21, 2015
    Inventor: Keith A. Webster
  • Publication number: 20130302293
    Abstract: Described herein are compositions, kits and methods for stimulating angiogenic functions of stem cells and/or progenitor cells having pro-angiogenic potential (e.g., endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs)) before transplantation (e.g., ex vivo cell therapy) based on the discovery that functional recovery of CD34+ cells from coronary artery disease (CAD) patients is improved by transfection of antagomirs against one or more miRs of a plurality of miRs identified to be over-expressed in cells from CAD patients. Described herein are methods to recover the functions of EPCs isolated from patients with cardiovascular disease (e.g., CAD or peripheral artery disease (PAD)) by bioengineering the cells with antagomirs and/or premirs to specific micro-RNAs. The bioengineered cells can then be used to treat patients with ischemic or ischemic-related disease (e.g., CAD or PAD) by autologous stem cell therapy.
    Type: Application
    Filed: November 11, 2011
    Publication date: November 14, 2013
    Inventor: Keith A. Webster
  • Publication number: 20130236433
    Abstract: The methods, compositions, cells and kits described herein are based on the discovery that stem cells, when injected into ischemic tissue of mammals, can be protected by preconditioning of the ischemic tissue with hypoxia-regulated human VEGF and human IGF-1. Methods, compositions, cells and kits for treating tissue injured by ischemia or at risk of ischemic injury in a subject are thus described herein.
    Type: Application
    Filed: November 10, 2011
    Publication date: September 12, 2013
    Inventor: Keith A. Webster
  • Publication number: 20130131152
    Abstract: Methods and compositions for the treatment of hypoxia associated disorders by directional angiogenesis/arteriogenesis. Conditionally silenced vectors expressing a therapeutic molecule under hypoxic conditions avoid chaotic vascularization and allow for the orderly growth of new vessels into damaged tissue.
    Type: Application
    Filed: November 1, 2010
    Publication date: May 23, 2013
    Applicant: UNIVERSITY OF MIAMI
    Inventor: Keith A. Webster
  • Patent number: 6893867
    Abstract: Expression vectors are disclosed that are comprised of (a) one or more silencer elements and conditionally inducible elements to form silencer-inducible regions and (b) promoters in operative linkage upstream of at least one expressed region. The expression vector thereby regulates expression of at least one downstream region by conditional silencing in which an expressed DNA region of a gene is transcribed to produce RNA transcripts, which may or may not be translated to produce polypeptides. Genetically engineered mammalian cells and non-human mammals can be made using such expression vectors through transfection and transgenesis techniques. Moreover, processes of making and using the aforementioned products are disclosed (e.g., the expression vector may be used diagnostically, therapeutically, or prophylactically).
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: May 17, 2005
    Inventor: Keith A. Webster
  • Publication number: 20040152650
    Abstract: Hypoxia-acidosis-associated cell death is mediated by BNIP3, a member of the Bcl-2 family of apoptosis-regulating proteins. Chronic hypoxia induced the expression and accumulation of BNIP3 mRNA and protein in cardiac myocytes but acidosis was required to activate the death pathway. Acidosis stabilized BNIP3 protein and increased the association with mitochondria. Cell death by hypoxia-acidosis was blocked by pretreatment with antisense BNIP3 oligonucleotides. The pathway included extensive DNA fragmentation and opening of the mitochondrial permeability transition pore but no apparent caspase activation. Overexpression of wild type BNIP3, but not a translocation-defective mutant activated cardiac myocyte death when the myocytes were acidotic or hypoxic.
    Type: Application
    Filed: July 22, 2003
    Publication date: August 5, 2004
    Inventor: Keith A. Webster
  • Patent number: 6218179
    Abstract: Methods and compositions relating to chimeric genes containing (i) a tissue-specific promoter and (ii) a hypoxia response enhancer element, both of which are operably linked to a selected gene, such as a reporter gene, therapeutic gene (e.g., bcl-2, NOS, catalase and SOD), or deleterious gene are disclosed. Expression of the selected gene is enhanced in the target tissue under hypoxia conditions, such as conditions encountered during episodes of ischemia and reperfusion. The methods and compositions may be used as therapeutics and/or diagnostics.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: April 17, 2001
    Assignee: SRI International
    Inventors: Keith A. Webster, Nanette H. Bishopric, Brian Murphy, Keith R. Laderoute, Christopher J. Green
  • Patent number: 5834306
    Abstract: Methods and compositions relating to chimeric genes containing (i) a tissue-specific promoter and (ii) a hypoxia response enhancer element, both of which are operably linked to a selected gene, such as a reporter gene, therapeutic gene (e.g., bcl-2, NOS, catalase and SOD), or deleterious gene are disclosed. Expression of the selected gene is enhanced in the target tissue under hypoxic conditions, such as conditions encountered during episodes of ischemia and reperfusion. The methods and compositions may be used as therapeutics and/or diagnostics.
    Type: Grant
    Filed: December 23, 1994
    Date of Patent: November 10, 1998
    Assignee: SRI International
    Inventors: Keith A. Webster, Nanette H. Bishopric